Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)
Citations Over TimeTop 11% of 2010 papers
Abstract
Selective estrogen receptor (ER) down-regulators (SERDs) reduce ERalpha protein levels as well as block ER activity and therefore are promising therapeutic agents for the treatment of hormone refractory breast cancer. Starting with the triarylethylene acrylic acid SERD 4, we have investigated how alterations in both the ligand core structure and the appended acrylic acid substituent affect SERD activity. The new ligands were based on high affinity, symmetrical cyclofenil or bicyclo[3.3.1]nonane core systems, and in these, the position of the carboxyl group was extended from the ligand core, either retaining the vinylic linkage of the substituent or replacing it with an ether linkage. Although most structural variants showed binding affinities for ERalpha and ERbeta higher than that of 4, only the compounds preserving the acrylic acid side chain retained SERD activity, although they could possess varying core structures. Hence, the acrylic acid moiety of the ligand is crucial for SERD-like blockade of ER activities.
Related Papers
- → Molecular Design Based on 3D Pharmacophores. Applications to 5-HT7Receptors(2004)21 cited
- → <i>In-Silico</i> Identification of Anticancer Compounds; Ligand-Based Pharmacophore Approach against EGFR Involved in Breast Cancer(2021)6 cited
- → Applications of Pharmacophore Mapping☆(2014)3 cited
- → PHARMACOPHORE BASED SCREENING OF EPICATECHIN AGAINST COLON CANCER(2012)1 cited
- → Computational Modeling of Selective Pharmacophores at the α 1 ‐Adrenergic Receptors(2008)2 cited